Model-based approach to sampling optimization in studies of antibacterial drugs for infants and young children

Yuji Orito1 | Makoto Kakara2 | Akira Okada1 | Naomi Nagai1

1Musashino University, Tokyo, Japan
2MSD K.K, Tokyo, Japan

Correspondence
Yuji Orito, Musashino University, 1-1-20 Shin-machi, Nishitokyo-shi, Tokyo, 202-8585, Japan.
Email: yuji.orito@merck.com

Funding information
No funding was received for this work.

Abstract
Clinical trials for pediatric indications and new pediatric drugs face challenges, including the limited blood volume due to the patients’ small bodies. In Japan, the Evaluation Committee on Unapproved or Off-labeled Drugs with High Medical Needs has discussed the necessity of pediatric indications against the background of a lack of Japanese pediatric data. The limited treatment options regarding antibiotics for pediatric patients are associated with the emergence of antibiotic-resistant bacteria. Regulatory guidelines promote the use of model-based drug development to reduce practical and ethical constraints for pediatric patients. Sampling optimization is one of the key study designs for pediatric drug development. In this simulation study, we evaluated the precision of the empirical Bayes estimates of pharmacokinetic (PK) parameters based on the sampling times optimized by published pediatric population PK models. We selected three previous PK studies of cefepime and ciprofloxacin in infants and young children as paradigms. The number of sampling times was reduced from original full sampling times to two to four sampling times based on the Fisher information matrix. We observed that the precision of empirical Bayes estimates of the key PK parameters and the predicted efficacy based on the reduced sampling times were generally comparable to those based on the original full sampling times. The model-based approach to sampling optimization provided a maximization of PK information with a minimum burden on infants and young children for the future development of pediatric drugs.

Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
The clinical trials in vulnerable populations, such as infants, face challenges, including the limited blood volume due to the small bodies. In Japan, the necessity of pediatric indications has been discussed against the background of a lack of Japanese pediatric data.

WHAT QUESTION DID THIS STUDY ADDRESS?
This simulation study aimed to apply a model-based approach to the development of antibiotics for pediatric patients to reduce practical and ethical constraints.
INTRODUCTION

In Japan, many drugs that are used in pediatric clinical settings are either unlicensed or used in an off-label manner. It was estimated that ~60%–70% of the package inserts of drugs prescribed in pediatric clinical settings in Japan did not provide a sufficient description of the dosage and administration for pediatric patients. The prescription of unlicensed or off-label drugs can result in an increased risk of adverse events and treatment failure. In general, when the indication(s) and the dosage for pediatric patients are specified in a drug’s package insert, the efficacy and safety data should be submitted to the regulatory agency. Japan’s Ministry of Health, Labour and Welfare (MHLW) has provided premiums to pharmaceutical companies to encourage the development of drugs for pediatric patients, and this has resulted in great progress in the access to already approved drug and the clinical trial environment. However, the rate of clinical trials for new drugs for pediatric patients was still ~20% of the rate for the total approved new drugs. Globally, clinical trials in pediatric patients are more challenging compared with those in adult patients because of the small number of eligible patients entering clinical trials, the difficulty in gaining consent from the patients’ parents, the limited blood volume of children, and the challenge of dose adjustments in accord with the physiological growth and organ maturation of children. Data for infants and young children with either acute or chronic disease in clinical trials are even more limited due to specific blood volume constraints under their regular clinical blood sampling.

In 2017, the World Health Organization (WHO) published a global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, and a WHO advisory panel stressed the importance of new antibiotics for pediatric populations. Since the WHO’s first analysis of the clinical antibacterial pipeline in 2017, eight new antibiotics have been approved by the US Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA), but the safety and effectiveness of these antibiotics for pediatric patients have not been established. The limited treatment options regarding antibiotics for pediatric patients are associated with the emergence of antibiotic-resistant bacteria.

The development of antibiotics for pediatric patients in Japan has often been initiated after pediatric indications for the antibiotics were approved in other countries and a sufficient amount of evidence from frequent-sampling pharmacokinetic (PK) studies and pediatric population PK models were already available. The E11 guideline of the International Conference on Harmonization (ICH; R1) describes the use of a population PK analysis, sparse sampling based on sampling optimization, and modeling and simulation in pediatric drug development in order to facilitate the design of protocols and to reduce practical and ethical constraints.

Our objective in the present study was to apply a model-based approach to pediatric drug development so that optimizing the sampling times by published population PK models would enable the maximization of PK information with a minimum burden on infants and young children. In addition, the predicted efficacy based on the optimized sampling times was evaluated. We focused on antibacterial drugs examined in PK studies of pediatric patients conducted in other countries and the pediatric population PK models.

METHODS

Drugs investigated

We selected cefepime (CFPM) and ciprofloxacin (CPFX) as model drugs with limited Japanese pediatric data. There are no ethnicity-related differences in the PK or dose setting for adults for these two drugs. CFPM is a fourth-generation cephalosporin that is widely used to treat infections caused by Gram-negative bacteria. Although no pediatric indication for CFPM is approved at this time in Japan, CFPM is used in an off-label manner. CPFX is one of the fluoroquinolones, the spectrum of which covers several clinically important pathogens—especially Gram-negative bacteria, including Pseudomonas aeruginosa. The pediatric indication for CPFX in Japan was approved as a public knowledge-based application based on both foreign data and the results of a survey of the use of CPFX in Japan reviewed by The Evaluation Committee on Unapproved or Off-labeled
Drugs with High Medical Needs, and no clinical trial had been conducted in Japanese pediatric patients.

**Population PK models**

Pediatric population PK models for CFPM and CPFX were reported based on pediatric clinical trials that used the traditional frequent sampling approach.\textsuperscript{15,17}

The pediatric population PK model for CFPM was developed based on PK data from 91 pediatric patients, including preterm infants who received CFPM by the i.v. route in two pediatric clinical trials.\textsuperscript{15,18,19} In those trials, the median gestational age of the patients was 29 weeks, their median age was 1.0 month, and their median body weight was 3.1 kg.

The pediatric population PK model for CFPM was summarized as follows:

\[
CL = WT^{0.75} \times 0.395 \times [−0.09 + 1.09 \times [1 − \exp(−0.00958 \times PMA)]] \times (SCR/0.6)^{-0.392}
\]

\[
V_{SS} = 0.406 \times WT \times (GA/30)^{-0.548}
\]

where WT is the patient’s body weight (kg), PMA is the post-menstrual age (weeks), SCR is the serum creatinine (mg/dl), and GA is the gestational age (weeks). The interindividual variabilities (percentage coefficient of variation [%CV]) in CL and \( V_{SS} \) in the pediatric population PK model for CFPM were 31.8% and 22.2%, respectively. The residual variability (%CV) was 66.3%.

The pediatric population PK model for CPFX was developed based on PK data from 150 pediatric patients, including 28 patients with cystic fibrosis (CF) who received CPFX by the p.o. and/or i.v. routes in 5 pediatric clinical trials.\textsuperscript{16,17,20–22} The patients’ median age was 2.5 years, and their median body weight was 13.5 kg. The pediatric population PK model for CPFX was summarized as follows:

\[
CL = 30.3 \times (WT/70)^{0.75} \times [1 + 0.045 \times (AGE - 2.5)]
\]

\[
V_C = 56.7 \times (WT/70)^{1.0}
\]

\[
V_p = 89.8 \times (WT/70)^{1.0}
\]

\[
Q = 37.5 \times (WT/70)^{0.75}
\]

\[
K_a = 1.27 \times [1 + (-0.611 \times CF)]
\]

\[
ALAG1 = 0.353 \text{ h}
\]

\[
F_1 = 61.1\%
\]

where WT and AGE are the patient’s body weight (kg) and age (years), respectively, and the variable CF = 1 for patients with CF and 0 for non-CF patients. The interindividual variabilities (%CV) were as follows: CL, 30.0%; \( V_C \), 34.6%; \( V_p \), 31.0%; Q, 40.6%; F1, 22.6%; and Ka, 49.8%. The residual variabilities (%CV) for the oral and i.v. data were 40.7% and 26.7%, respectively. The shared additive residual variance component was 0.00169 (SD = 0.0411 mg/L).

**Optimal sampling scenario**

For the sampling optimization in the present study, we selected three studies conducted outside Japan. CFPM study 1, CPFX study 1, and CPFX study 2 enrolled infants and young children with traditional frequent sampling times,\textsuperscript{16,18,20} and these were used in developing the pediatric population PK models for CFPM or CPFX.\textsuperscript{15,17}

Table 1 shows the brief study design and characteristics in each study. We selected two specific infant groups (2 to <6 months and 6 to <24 months) in the CFPM study 1 for the present study. We used the model-based approach to determine optimal sampling scenarios. This approach relies on the Fisher information matrix for a nonlinear mixed effect model. We selected Population Fisher Information Matrix (PFIM) version 4.0 from among the several software tools that are available for population design evaluations,\textsuperscript{23–25} as the PFIM is the only tool that uses the free software R. We
used the Fedorov-Wynn algorithm, which optimizes over a discrete set of times, by using the sampling times from the original design, avoiding clinically unfeasible sampling times. The ICH E11 (R1) guideline recommends sparse sampling approaches in which each patient contributes as few as two to four observations at predetermined times to an overall “population area under the curve,” and we therefore determined the optimal sampling scenarios with two (S2), three (S3), and four (S4) sampling times from the original design by PFIM. The number of sampling times must be as limited as possible for a vulnerable population, such as infants, and we therefore evaluated an extended scenario (S1G3) with one sampling time per patient. For this extended scenario (S1G3), one sample in each patient was randomly collected from the optimized three sampling times (S3).

Simulation of drug concentrations

We generated virtual pediatric populations from CFPM study 1, CPFX study 1, and CPFX study 2 for the simulation of the time-concentration profiles. The age (or PMA), body WT, and SCR for the virtual pediatric populations were generated by log normal distribution based on the patients’ characteristics in Table 1. In CFPM study 1, the body WT and the GA in both of the infant groups were not reported. For these groups, the body WT was generated by the distribution by using the standard age versus body WT growth charts, and the GA was 36 weeks by a fixed value. Drug concentrations were simulated 1000 times in each study based on the population PK models by the software NONMEM version 7.4 (ICON Development Solutions, Ellicott City, MD). Data processing was performed with R version 3.5.0.

Assessment of the precision of PK parameters

Using the simulated drug concentrations, individual Bayes PK parameters (e.g., CL, VSS, Ka, VC, VP, Q, and F1) were estimated based on the population PK models in original design and optimal sampling scenarios (i.e., S4, S3, S2, and S1G3). The area under the drug concentration-time curve (AUC) is one of the key PK parameters associated with the efficacy and/or safety of antibacterial drugs, and we assessed for the appropriateness of optimal sampling scenarios. Each individual AUC is calculated from CL (or CL/F) and dosage. The relative bias for each individual AUC in each optimal sampling scenario compared with those in original design was calculated as follows:

\[
\% \text{Bias}(\text{AUC}) = \left[ \frac{1}{N} \sum_{i=1}^{N} \left( \frac{\text{AUC}_{i,\text{optimal}} - \text{AUC}_{i,\text{original}}}{\text{AUC}_{i,\text{original}}} \right) \right] \times 100\%
\]

where \( \text{AUC}_{i,\text{optimal}} \) and \( \text{AUC}_{i,\text{original}} \) are the individual AUCs of the \( i \)th patient in each optimal sampling scenario and the original design, respectively. \( N \) is the number of patients in each study. A box plot represents 1000 simulated \( \% \text{Bias} (\text{AUC}) \) in each scenario for the assessment of the precision of the AUC.

Furthermore, the precision of the individual Bayes estimates in each optimal sampling scenario was also assessed. The relative bias for the individual Bayes PK parameters in each optimal sampling scenario compared with those in the original design was calculated as follows:

\[
\% \text{Bias}(\theta_k) = \frac{\theta_{k,\text{optimal}} - \theta_{k,\text{original}}}{\theta_{k,\text{original}}} \times 100\%
\]

where \( \theta_{k,\text{optimal}} \) and \( \theta_{k,\text{original}} \) are the empirical Bayes estimates of the PK parameter \( k \) (e.g., CL, VSS, Ka, VC, VP, Q, and F1) of individuals based on each optimal sampling scenario and the original design, respectively. We calculated the median and 10th and 90th percentiles from \( \% \text{Bias} (\theta_k) \) in each simulation. A table summarizes the median of 1000 simulated medians and 10th to 90th percentiles, respectively.

PK/pharmacodynamic target attainment analyses

The PK/pharmacodynamic (PD) target that best correlates with the efficacy of CFPM is the percentage of time that the free plasma concentrations are above a minimum inhibitory concentration (\%\( fT > \text{MIC} \)). Because several recent articles used the optimized 60% target attainment of CFPM, we used a \%\( fT > \text{MIC} \) of 60% as the target value for the efficacy. Using the estimated individual Bayes PK parameters for CFPM study 1, \( fT > \text{MIC} \) in the original design and each optimal sampling scenario was calculated assuming an unbound free fraction of 80% as follows:

\[
fT > \text{MIC} = \frac{\ln \text{Dose}/(Vf/f) - \ln \text{MIC}}{CL/Vf}
\]

where \( Vf \) is the volume of distribution at the terminal phase, and \( f \) is the unbound free fraction.

The individual Bayes PK parameters were used to calculate the \%\( fT > \text{MIC} \). The probability of target attainment (PTA) of the \%\( fT > \text{MIC} \) of greater than 60% was calculated for various MICs (1, 2, 4, 8, 16, and 32 μg/ml) in each simulation. A table summarizes the mean and the SD of the PTA values of 1000 simulations, respectively.

The PK/PD target that best correlates with the efficacy of CPFX is the ratio of the area under the unbound concentration–time curve to the MIC (fAUC/MIC). Since the PD model for the probability of cure was established, we used the fAUC/MIC of 86 as the target value for the
efficacy. Using the estimated individual Bayes PK parameters in CPFX study 1 and CPFX study 2, the fAUC/MIC in the original design and each optimal sampling scenario was calculated assuming an unbound free fraction of 70% as follows:

\[
fAUC = f \times \frac{Dose}{CL(\text{or } CL/F)}
\]

The individual Bayes PK parameters were used to calculate the fAUC/MIC. The PTA of the fAUC/MIC of greater than 86 was calculated for various MICs (0.125, 0.25, and 0.5 μg/ml) in each simulation. A table summarizes the mean and the SD of the PTA values of 1000 simulations, respectively.

**RESULTS**

**Optimal sampling scenario**

We observed that the sampling times were optimized by PFIM and the optimal sampling times were different among studies. The optimization of the design for 3 studies with 16 or 18 sampling times was performed by PFIM in 4 (S4), 3 (S3), and 2 (S2) sampling times (Table 2). There were several overlapped sampling times between S2 and S4 in each study. For S1G3, the patients were allocated randomly to 3 groups that follow 1 of 3 sampling times based on S3 (Table 2).

For CFPM study 1 (i.v. infusion for 0.5 h), sampling times between 0.5 and 2 h were selected in the initial distribution phase, and sampling times between 2 and 8 h (predose at the steady-state) were selected in the terminal elimination phase. For CPFX study 1 (oral administration), sampling times between 0.5 and 4 h were selected in the absorption phase and the initial distribution phase, and sampling times between 4 and 6 h were selected in the terminal elimination phase. For CPFX study 2 (i.v. infusion for 1 h), sampling times between 0.5 and 2 h were selected in the initial distribution phase, and sampling times between 2 and 12 h were selected in the terminal elimination phase.

**Assessment of the precision of PK parameters**

As shown by the box plots of %Bias (AUC) for CFPM study 1, CPFX study 1, and CPFX study 2 from each set of 1000 simulations (Figure 1), the median of %Bias (AUC) was generally comparable among S4, S3, and S2 in each study. There was no significant variability of %Bias (AUC) at S4, S3, or S2 (within the range of ±20%), but large variability was observed at S1G3 (within the range of ±30%) despite the use of the same sampling times as S3 because of one sampling time in each patient.

The median and 10th and 90th percentiles of %Bias (CL) for the AUC calculation are presented in Table 3. For CFPM study 1 and CPFX study 1, the median of %Bias (CL) shows the slightly overestimated CL values (2.36%–3.29%) at S4, S3, and S2. The median of %Bias (CL) at S1G3 were −0.712% and 1.89%, respectively. For CPFX study 2, the median of %Bias (CL) at S4, S3, S2, and S1G3 were between −0.115% and 1.28%.

The other PK parameters (i.e., VSS, KA, Vc, VP, Q, and F1) were calculated as a reference in this simulation study. Larger variabilities of %Bias were observed for several PK parameters at fewer sampling times.

**PK/PD target attainment**

For the original design and optimal sampling scenarios in CFPM study 1 (50 mg/kg i.v. every 8 h), the PTA of greater than 60% for the various MICs are presented in Table 4. The PTA of CFPM for various MICs was generally comparable with the original design.

### TABLE 2  Sampling times of original design and optimal sampling scenarios

| Study       | Sampling day | Original design | **Optimal sampling scenarios** | Four sampling times (S4) | Three sampling times (S3) | Two sampling times (S2) | One sampling timea (S1G3) |
|-------------|--------------|-----------------|-------------------------------|--------------------------|---------------------------|-------------------------|--------------------------|
| CFPM study 1| Day1 Steady-state | 0, 0.5, 0.75, 1, 2, 4, 6, 8 h | 0.5, 0.75, 2, 8 h | 0.5, 2 h | 0 h | 2, 8 h | Day 1 0.5 h, 2 h or Steady-state 0 h |
| CFPM study 1| Day1 Steady-state | 0, 0.5, 1, 2, 4, 6, 8 h | 0.5 h | 0.5, 4 h | 4 h | – | Day 1 0.5 h, 4 h or Steady-state 4 h |
| CFPM study 2| Day1 Steady-state | 0, 0.5, 1, 2, 3, 4, 6, 8, 12 h | 0.5, 2, 4, 12 h | 1, 3, 12 h | 4, 12 h | – | Day 1 1 h, 3 h or 12 h |

Abbreviations: CFPM, cefepime; CPFX, ciprofloxacin.

aThe patients were allocated randomly to three groups that follow one of three sampling times based on S3.
among the original design and all four optimal sampling scenarios. All mean PTA values approached 1.00 when the MICs were between 1 and 4 μg/ml. All mean PTA values in CFPM study 1 at the MIC of 8, 16, and 32 μg/ml were 0.91–0.97, 0.65–0.78, and 0.09–0.19, respectively.

For the original design and optimal sampling scenarios in CPFX study 1 (10 mg/kg p.o. every 8 h) and CPFX study 2 (10 mg/kg i.v. every 12 h), the PTA of greater than 86 for various MICs are presented in Table 5. As an additional analysis, the PTA at the recommended regimen (15 mg/kg p.o. every 8 h and 10 mg/kg i.v. every 8 h) in the pediatric dosage guideline was calculated. The PTA of CPFX for various MICs was generally comparable among the original design and all four optimal sampling scenarios in both CPFX study 1 and CPFX study 2. All mean PTA values approached 1.00 when the MICs were at 0.125 μg/ml. All mean PTA values for the study regimen in CPFX study 1 and CPFX study 2 at the MIC of 0.25 μg/ml were 0.22–0.35 and 0.33–0.42, respectively. All mean PTA values for the recommended regimens (15 mg/kg p.o. every 8 h and 10 mg/kg i.v. every 8 h) at the MIC of 0.25 μg/ml were 0.74–0.89 and 0.87–0.97, respectively.

**DISCUSSION**

Our results indicated that it was possible to estimate the AUC, which is one of the key PK parameters associated with the efficacy and/or safety of antibacterial drugs with a reduction to fewer sampling times. It was possible to...
| Table 3 | PK parameter relative bias to original design in each optimal sampling scenario |
|---------|-------------------------------------------------------------------------|
| **Study** | **Parameter** | **Four sampling times (S4)** | **Three sampling times (S3)** | **Two sampling times (S2)** | **One sampling time (S1G3)** |
|         |                | **Bias (%)** | **Bias (%)** | **Bias (%)** | **Bias (%)** | **Bias (%)** |
| CFPM study 1 | CL | 3.20 | −14.0 | 29.8 | 2.53 | −14.0 | 27.8 | 3.22 | −14.5 | 31.0 | −0.712 | −24.8 | 32.9 |
|         | $V_{SS}$ | −1.94 | −14.0 | 12.5 | −1.96 | −13.3 | 14.0 | −2.13 | −14.4 | 14.4 | −0.456 | −14.4 | 20.0 |
| CPFX study 1 | CL | 2.36 | −8.68 | 18.2 | 3.29 | −12.3 | 24.9 | 3.05 | −15.8 | 30.7 | 1.89 | −18.9 | 29.6 |
|         | $K_a$ | −1.33 | −18.8 | 20.4 | −1.48 | −22.3 | 20.4 | −1.78 | −23.4 | 23.8 | 1.06 | −31.1 | 49.8 |
|         | $V_C$ | −0.275 | −11.6 | 13.1 | 0.678 | −10.4 | 16.8 | 1.35 | −11.2 | 19.0 | −0.780 | −18.5 | 22.9 |
|         | $V_P$ | −3.28 | −21.9 | 17.4 | −2.00 | −22.2 | 21.9 | −1.30 | −22.3 | 23.3 | −2.52 | −23.8 | 24.2 |
|         | $Q$ | −2.33 | −20.5 | 19.9 | −1.19 | −19.4 | 23.2 | −0.560 | −18.7 | 24.1 | −2.73 | −23.4 | 26.8 |
|         | $F_1$ | 0.550 | −8.73 | 10.2 | −0.602 | −9.07 | 7.42 | −0.688 | −11.2 | 9.11 | 0.788 | −12.1 | 13.6 |
| CPFX study 2 | CL | 1.28 | −10.8 | 16.7 | 0.811 | −13.2 | 17.9 | −0.115 | −17.3 | 21.8 | 0.810 | −21.6 | 31.7 |
|         | $V_C$ | 0.681 | −15.5 | 25.5 | 0.777 | −17.9 | 28.2 | −1.52 | −30.1 | 38.9 | −0.238 | −26.5 | 37.2 |
|         | $V_P$ | 0.207 | −16.7 | 22.2 | 0.599 | −17.3 | 25.8 | −1.84 | −25.5 | 29.6 | −0.937 | −26.9 | 33.0 |
|         | $Q$ | 0.843 | −19.9 | 32.9 | 1.61 | −20.8 | 36.3 | −2.12 | −34.6 | 47.8 | −0.671 | −31.0 | 45.9 |

Abbreviations: CFPM, cefepime; CL, clearance; CPFX, ciprofloxacin; $F_1$, oral bioavailability fraction; P10, 10th percentile; P90, 90th percentile; $K_a$, absorption rate constant; PK, pharmacokinetic; $Q$, intercompartmental clearance; $V_C$, volume of distribution for central compartment; $V_P$, volume of distribution for peripheral compartment; $V_{SS}$, distribution at steady state.
estimate the AUC even with a single sampling time per patient (S1G3), but the interpretation of individual estimated AUC values requires caution. Our present findings demonstrated that the precision of the individual CL (used for AUC calculation) estimated by the reduced optimal sampling times, even with only two sampling times, was
The sampling times by using data obtained from adults. In a study of an antimalarial drug for pediatric patients, Japan, but it may also be possible to investigate the optimization from pediatric studies conducted outside Japan, blood sampling in these studies. We investigated the sampling optimization described herein will help reduce the burden of agencies and as investigator-initiated trials are likely to provide the valuable information for therapeutic drug monitoring and the administration plans for antibiotics in clinical settings. We foresee that the accumulation of pediatric data will enrich physiologically based PK models, including those accounting for patients’ growth, and discussions regarding the use and extrapolations of data from foreign sources will continue to be fruitful.

ACKNOWLEDGMENTS

The authors would like to thank to Hiroyuki Yoshitsugu (MSD K.K.) and Mari Shiomi (MSD K.K.) whose comments and suggestions were of inestimable value for this study.

CONFLICT OF INTEREST

Y.O. and M.K. are current employees of MSD K.K., and may hold stock and/or stock options in the company. MSD K.K.
was not involved in this study. All other authors declared no competing interests for this work.

**AUTHOR CONTRIBUTIONS**

Y.O., M.K., A.O., and N.N. wrote the manuscript. Y.O., M.K., A.O., and N.N. designed the research. Y.O. performed the research. Y.O. and M.K. analyzed the data. Y.O. and M.K. contributed new reagents/analytical tools.

**REFERENCES**

1. Nakagawa M. Pediatric drug development in Japan from the perspective of academia. *J Clin Ther Med*. 2018;34:143-146.[in Japanese].
2. Tsukamoto K, Carroll KA, Onishi T, Matsumaru N, Brasseur D, Nakamura H. Improvement of pediatric drug development: regulatory and practical frameworks. *Clin Ther*. 2016;38:574-581.
3. Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. *Lancet*. 2004;364:803-811.
4. Sammons HM, Starkey ES. Ethical issues of clinical trials in children. *Paediatr Child Health*. 2012;22:47-50.
5. Cella M, Knibbe C, Danhof M, Della Pasqua O. What is the right dose for children? *Br J Clin Pharmacol*. 2010;70:597-603.
6. Howie SR. Blood sample volumes in child health research: review of safe limits. *Bull World Health Organ*. 2011;89:46-53.
7. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1. Accessed May 21, 2020.
8. World Health Organization. 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. https://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/. Accessed May 21, 2020.
9. Okada T, Sato Y, Toyonaga Y, Hanaki H, Sunakawa K. Nationwide survey of Streptococcus pneumoniae drug resistance in the pediatric field in Japan. *Pediatr Int*. 2016;58:192-201.
10. Miyashita N, Kawai Y, Akaike H, et al. Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. *BMC Infect Dis*. 2012;12:126.
11. ICH Harmonised Guideline. Addendum to ICH E11: Clinical Investigation of Medicinal Products in the Paediatric Population. E11(R1). https://www.ich.org/page/efficacy-guidelines. Accessed May 27, 2020.
12. Bellanti F, Della Pasqua O. Modelling and simulation as research tools in paediatric drug development. *Eur J Clin Pharmacol*. 2011;67(Suppl 1):75-86.
13. Medical Package Insert. Maxipime for injection 0.5 g. Maxipime for injection 1 g. (18th ed.) Revised March 2019. [in Japanese].
14. Medical Package Insert. Ciproxan–I.V.200. Ciproxan–I.V.400. (34th ed.) Revised September 2019. [in Japanese].
15. Shoji K, Bradley JS, Reed MD, van den Anker JN, Domonoske C, Capparelli EV. Population pharmacokinetic assessment and pharmacodynamic implications of pediatric cefepime dosing for susceptible-dose-dependent organisms. *Antimicrob Agents Chemother*. 2016;60:2150-2156.
16. Peltola H, Ukkonen P, Saxen H, Stass H. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. *Pediatrics*. 1998;101:658-662.
17. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. *J Clin Pharmacol*. 2003;43:698-710.
18. Reed MD, Yamashita TS, Knupp CK, Vazey JM Jr, Blumer JL. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. *Antimicrob Agents Chemother*. 1997;41:1783-1787.
19. Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. *Antimicrob Agents Chemother*. 2005;49:2760-2766.
20. Lipman J, Gous AGS, Mathivha LR et al. Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? *Intensive Care Med*. 2002;28:493-500.
21. Schaefer HG, Stass H, Wedgewood J, et al. Pharmacokinetics of cefepime in pediatric cystic fibrosis patients. *Antimicrob Agents Chemother*. 1996;40:29-34.
22. Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA. Pharmacokinetic disposition of sequential intravenous/oral cefepime in pediatric cystic fibrosis patients with acute pulmonary exacerbation. *Pediatr Infect Dis J*. 1997;16:112-117.
23. Dumont C, Lestini G, Le Nagard H et al. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models. *Comput Methods Programs Biomed*. 2018;156:217-229.
24. Nyberg J, Bazzoli C, Ogungbenro K et al. Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies. *Br J Clin Pharmacol*. 2015;79:6-17.
25. Mentre F, Chenel M, Comets E et al. Current use and developments needed for optimal design in pharmacometrics: a study performed among DDMoRe’s European Federation of Pharmaceutical Industries and Associations Members. *CPT Pharmacometrics Syst Pharmacol*. 2013;2:e46.
26. Retout S, Comets E, Samson A, Mentre F. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. *Stat Med*. 2007;26:5162-5179.
27. Centers for Disease Control and Prevention. National Center for Health Statistics. Data table of infant weight-for-age charts. https://www.cdc.gov/growthcharts/html_charts/wtageinf.htm. Accessed May 27, 2020.
28. Downes KJ, Hahn A, Wiles J, Courter JD, Vinks AA. Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. *Int J Antimicrob Agents*. 2014;43:223-230.
29. Bauer KA, West JE, O’Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. *Antimicrob Agents Chemother*. 2013;57:2907-2912.
30. Kassel LE, Van Matre ET, Foster CJ, et al. A randomized pharmacokinetic and pharmacodynamic evaluation of every 8-hour and 12-hour dosing strategies of vancomycin and cefepime in neurocritically ill patients. *Pharmacotherapy*. 2018;38:921-934.
31. Squibb B-M. Maxipime Prescribing Information. Princeton, NJ: Bristol-Myers Squibb; 2009.
32. Zelenitsky S, Ariano R, Harding G, Forrest A. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using
clinical outcome-based Monte Carlo simulations. *Antimicrob Agents Chemother*. 2005;49:4009-4014.

33. Bergogne-Berezin E. Clinical role of protein binding of quinolones. *Clin Pharmacokinet*. 2002;41:741-750.

34. Baum VC, Bax R, Heon D, Yang Z, Sakiyama M. Pediatric drug regulation: international perspectives. *Paediatr Anaesth*. 2019;29:572-582.

35. Petit C, Jullien V, Samson A, et al. Designing a pediatric study for an antimalarial drug by using information from adults. *Antimicrob Agents Chemother*. 2016;60:1481-1491.

36. Santamaria E, Estevez JA, Riba J, Izquierdo I, Valle M. Population pharmacokinetic modelling of rupatadine solution in 6–11 year olds and optimisation of the experimental design in younger children. *PLoS One*. 2017;12:e0176091.

37. Zhao Y, Yao B-F, Kou C et al. Developmental population pharmacokinetics and dosing optimization of cefepime in neonates and young infants. *Front Pharmacol*. 2020;11:14.

38. Leroux S, Turner MA, Guellec CB-L, et al. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. *Clin Pharmacokinet*. 2015;54:1273-1285.

**How to cite this article:** Orito Y, Kakara M, Okada A, Nagai N. Model-based approach to sampling optimization in studies of antibacterial drugs for infants and young children. *Clin Transl Sci*. 2021;14:1543–1553. [https://doi.org/10.1111/cts.13018](https://doi.org/10.1111/cts.13018)